Literature DB >> 10084445

Antidepressant exacerbation of spasticity.

K A Stolp-Smith1, M C Wainberg.   

Abstract

Patients with spinal cord injury (SCI) may develop depression. This may be related to adjustment to living with an SCI in addition to dealing with complications of the injury, such as spasticity. Pharmacologic treatment of depression can be difficult because of neurochemical and receptor changes that are associated with SCI. Newer antidepressant agents are purported to have selective activity by alteration of serotonergic neurotransmission. A case report is presented that illustrates exacerbation of spasticity by this family of antidepressant medications. Mechanisms possibly explaining this exacerbation of spasticity are the effects of serotonin on motor neuron and reflex activity, denervation supersensitivity, and the serotonin syndrome. Understanding the relationship between serotonergic systems and spasticity can be important in treating depression in patients with spasticity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10084445     DOI: 10.1016/s0003-9993(99)90148-x

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  14 in total

1.  Management of Mental Health Disorders, Substance Use Disorders, and Suicide in Adults with Spinal Cord Injury: Clinical Practice Guideline for Healthcare Providers.

Authors:  Charles H Bombardier; Casey B Azuero; Jesse R Fann; Donald D Kautz; J Scott Richards; Sunil Sabharwal
Journal:  Top Spinal Cord Inj Rehabil       Date:  2021

2.  Managing loss of intrathecal baclofen efficacy: Review of the literature and proposed troubleshooting algorithm.

Authors:  Aaron Boster; Jacqueline Nicholas; Mary Pat Bartoszek; Colleen O'Connell; Chima Oluigbo
Journal:  Neurol Clin Pract       Date:  2014-04

3.  Up-regulation of 5-HT2 receptors is involved in the increased H-reflex amplitude after contusive spinal cord injury.

Authors:  Jae K Lee; Christopher S Johnson; Jean R Wrathall
Journal:  Exp Neurol       Date:  2006-10-23       Impact factor: 5.330

4.  Divergent modulation of clinical measures of volitional and reflexive motor behaviors following serotonergic medications in human incomplete spinal cord injury.

Authors:  Christopher K Thompson; T George Hornby
Journal:  J Neurotrauma       Date:  2013-04-03       Impact factor: 5.269

Review 5.  Strategies to augment volitional and reflex function may improve locomotor capacity following incomplete spinal cord injury.

Authors:  Kristan A Leech; Hyosub E Kim; T George Hornby
Journal:  J Neurophysiol       Date:  2017-11-01       Impact factor: 2.714

6.  A randomized controlled trial of venlafaxine XR for major depressive disorder after spinal cord injury: Methods and lessons learned.

Authors:  Charles H Bombardier; Jesse R Fann; Catherine S Wilson; Allen W Heinemann; J Scott Richards; Ann Marie Warren; Larry Brooks; Catherine A Warms; Nancy R Temkin; Denise G Tate
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

Review 7.  A benefit-risk assessment of baclofen in severe spinal spasticity.

Authors:  Alessandro Dario; Giustino Tomei
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

8.  A Primary Care Provider's Guide to Spasticity Management in Spinal Cord Injury.

Authors:  Philippines Cabahug; Charles Pickard; Travis Edmiston; Jesse A Lieberman
Journal:  Top Spinal Cord Inj Rehabil       Date:  2020

9.  Effects of serotonergic medications on locomotor performance in humans with incomplete spinal cord injury.

Authors:  Kristan A Leech; Catherine R Kinnaird; T George Hornby
Journal:  J Neurotrauma       Date:  2014-06-20       Impact factor: 5.269

10.  Soleus H-reflex recruitment is not altered in persons with chronic spinal cord injury.

Authors:  Sheila M Schindler-Ivens; Richard K Shields
Journal:  Arch Phys Med Rehabil       Date:  2004-05       Impact factor: 3.966

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.